Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03194893 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

StatusCompleted
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 78 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Results posted: Oct 9, 2026 Site details revised at 1 of 29 sites Show 1 more changeShow less
    • Site details revised at 1 of 29 sites
  2. Enrollment reduced: 200 → 50 participants Trial completed · Primary and study completion moved earlier from May 30, 2026 to Sep 18, 2025v77 Show 2 more changesShow less
    • Trial completed
    • Primary and study completion moved earlier from May 30, 2026 to Sep 18, 2025
  3. 2 versions Re-verified since Feb 18, 2026, no change to tracked fieldsv75-v76
  4. Primary and study completion dates: Oct 31, 2025 to May 30, 2026v74
  5. 2 versions Re-verified since Aug 7, 2025, no change to tracked fieldsv72-v73
Show 43 earlier versionsHide 43 earlier versions
  1. Trial status: Recruiting to Active, Not Recruiting Study sites: 30 to 29 · Primary and study completion dates: Jun 12, 2026 to Oct 31, 2025v71 Show 2 more changesShow less
    • Study sites: 30 to 29
    • Primary and study completion dates: Jun 12, 2026 to Oct 31, 2025
  2. 3 versions Re-verified since Feb 10, 2025, no change to tracked fieldsv68-v70
  3. Study sites: 35 to 30v67
  4. 6 versions Re-verified since Jun 11, 2024, no change to tracked fieldsv61-v66
  5. Primary and study completion dates: Jun 12, 2024 to Jun 12, 2026v60
  6. 5 versions Re-verified since Dec 1, 2023, no change to tracked fieldsv55-v59
  7. Site details revised at 1 of 35 sitesv54
  8. Study sites: 34 to 35v53
  9. Site details revised at 1 of 34 sitesv52
  10. Re-verified, no change to tracked fieldsv51
  11. Study sites: 32 to 34v50
  12. Re-verified, no change to tracked fieldsv49
  13. Study sites: 30 to 32v48
  14. Trial status: Active, Not Recruiting to Recruiting Site details revised at 30 of 30 sitesv47 Show 1 more changeShow less
    • Site details revised at 30 of 30 sites
  15. Study sites revised (30)v46 See this version in full on ClinicalTrials.gov ↗
  16. Site details revised at 1 of 30 sitesv45
  17. 4 versions Re-verified since Apr 14, 2022, no change to tracked fieldsv41-v44
  18. Study sites: 31 to 30v40
  19. Site details revised at 1 of 31 sitesv39
  20. Site details revised at 1 of 31 sitesv38
  21. 2 versions Re-verified since Jan 8, 2021, no change to tracked fieldsv36-v37
  22. Trial status: Recruiting to Active, Not Recruiting Site details revised at 31 of 31 sitesv35 Show 1 more changeShow less
    • Site details revised at 31 of 31 sites
  23. Re-verified, no change to tracked fieldsv34
  24. Site details revised at 1 of 31 sitesv33
  25. Site details revised at 3 of 31 sitesv32
  26. Site details revised at 1 of 31 sitesv31
  27. Re-verified, no change to tracked fieldsv30
  28. Site details revised at 1 of 31 sitesv29
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Roche/Genentech
366 trials monitored
See 33 trials at risk
The purpose of this study is to provide continued treatment with alectinib or crizotinib as applicable to participants with ALK- or RET positive cancer who were previously enrolled in any Roche-sponsored alectinib study and who are deriving continued clinical benefit from alectinib or crizotinib in the parent trial at the time of parent trial closure.
Trial Details
NCT Number NCT03194893
Lead Sponsor Hoffmann-La Roche
Conditions Neoplasms
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov